Rottinghaus Scott T.
Transaction: 08/08/2026
SELL
Change
-1,467
Price
$13.34
Filing
08/10/2026
Type
SELL
Enanta Pharmaceuticals, Inc.
ENTA • Biotechnology
$14.08
▲ +0.06 (+0.43%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$407.73M
Growth
3.7%
Cash Flow
0/5
Trend
Negative
Evidence
Healthy liquidity · 4.21High debt level · 3.11Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:13 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$14.08
Change0.43%
Shares Out28.96M
Market Cap$407.73M
Enterprise Value$273.88M
52W Range7.05 - 17.15
Beta0.93
P/E-6.45
P/S6.25
P/B4.03
P/FCF-11.04
EV/Sales4.20
Price$14.08
Change0.43%
Shares Out28.96M
Market Cap$407.73M
Enterprise Value$273.88M
52W Range7.05 - 17.15
Beta0.93
P/E-6.45
P/S6.25
P/B4.03
P/FCF-11.04
EV/Sales4.20
EV/EBITDA-3.79
EV/FCF-7.41
Earnings Yield-15.51%
FCF Yield-9.06%
Dividend Yield0.00%
Gross Margin92.98%
Oper. Margin-130.65%
Profit Margin-125.36%
Debt/Eq3.11
Current Ratio4.21
Quick Ratio4.21
Revenue 5Y3.66%
Target$20.00
Target Upside42.05%
Target Median$20.00
Target Range20.00 - 20.00
Volume148.85K
Avg Volume190.96K
EPS Surprise0.01
Investment DNA
How strong this company looks for long-term investors
36
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
58/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
71/100
Why this score▼
Healthy liquidity · 4.21High debt level · 3.11Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 19 analyst votes · 2026-09-05
82/100
Bullish
Bullish
14
Hold
3
Bearish
2
Price Target
2026-08-14
Low
$20.00
Mean
$20.00
Median
$20.00
High
$20.00
Insider Transactions
Recent executive and insider activity
CARTER BRUCE L A
Transaction: 03/11/2026
BUY
Change
+20,000
Price
$14.17
Filing
03/13/2026
Type
BUY
FOLETTA MARK G
Transaction: 03/11/2026
BUY
Change
+20,000
Price
$14.17
Filing
03/13/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Rottinghaus Scott T. | SELL | -1,467 | $13.34 | 08/08/2026 | 08/10/2026 |
| CARTER BRUCE L A | BUY | +20,000 | $14.17 | 03/11/2026 | 03/13/2026 |
| FOLETTA MARK G | BUY | +20,000 | $14.17 | 03/11/2026 | 03/13/2026 |
| Hata Yujiro S | BUY | +20,000 | $14.17 | 03/11/2026 | 03/13/2026 |
| Peterson Kristine | BUY | +20,000 | $14.17 | 03/11/2026 | 03/13/2026 |
| Russell Lesley | BUY | +20,000 | $14.17 | 03/11/2026 | 03/13/2026 |
| Vance Terry | BUY | +20,000 | $14.17 | 03/11/2026 | 03/13/2026 |
| Luly Jay R. | BUY | +4,800 | Not reported | 02/12/2026 | 02/13/2026 |
| Or Yat Sun | BUY | +1,650 | Not reported | 02/12/2026 | 02/13/2026 |
| Rottinghaus Scott T. | BUY | +1,650 | Not reported | 02/12/2026 | 02/13/2026 |
| Kieffer Tara Lynn | BUY | +1,575 | Not reported | 02/12/2026 | 02/13/2026 |
| Luu Brendan | BUY | +1,575 | Not reported | 02/12/2026 | 02/13/2026 |
| Kowalsky Matthew Paul | BUY | +1,318 | Not reported | 02/12/2026 | 02/13/2026 |
| Luly Jay R. | SELL | -4,743 | $14.23 | 12/05/2025 | 12/05/2025 |
| Or Yat Sun | SELL | -2,390 | $14.23 | 12/05/2025 | 12/05/2025 |
| Kieffer Tara Lynn | SELL | -2,106 | $14.23 | 12/05/2025 | 12/05/2025 |
| Luu Brendan | SELL | -1,394 | $14.23 | 12/05/2025 | 12/05/2025 |
| Rottinghaus Scott T. | SELL | -798 | $14.23 | 12/05/2025 | 12/05/2025 |
| Trout Harry R. III | SELL | -542 | $14.23 | 12/05/2025 | 12/05/2025 |
| Capps Kathleen S. | SELL | -323 | $14.23 | 12/05/2025 | 12/05/2025 |